Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MODICON 21 vs DEMULEN 1/50-28
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination estrogen-progestin contraceptive; suppresses gonadotropins (FSH, LH) from pituitary via negative feedback, inhibiting ovulation; increases cervical mucus viscosity, impeding sperm penetration; induces endometrial thinning.
Combination oral contraceptive: Ethinyl estradiol and ethynodiol diacetate suppress gonadotropin secretion (LH, FSH) via negative feedback, inhibiting ovulation. Ethynodiol diacetate also increases cervical mucus viscosity and induces endometrial changes.
Prevention of pregnancy
FDA: Prevention of pregnancy,Off-label: Treatment of acne vulgaris, dysmenorrhea, endometriosis-related pain, menstrual irregularity
One tablet (norethindrone 0.5 mg and ethinyl estradiol 0.035 mg) orally once daily for 21 consecutive days, followed by 7 drug-free days.
One tablet orally once daily for 28 consecutive days per cycle.
Terminal elimination half-life: 12–18 hours; clinical context: steady-state reached after 3–5 days of daily dosing
Ethinylestradiol: terminal elimination half-life ~13-27 hours (mean ~17 hours); ethynodiol diacetate (as norethindrone): terminal elimination half-life ~8-11 hours; clinical context: achieved steady-state within 5-10 days; accumulation not significant due to dose interval.
Ethinyl estradiol undergoes hepatic CYP3A4-mediated hydroxylation and conjugation; norethindrone is reduced and conjugated in liver.
Ethinyl estradiol: CYP3A4; undergoes first-pass metabolism with sulfation and glucuronidation. Ethynodiol diacetate: Deacetylated to norethynodrel, then extensively metabolized via reduction and conjugation.
Renal (80% as metabolites, 20% unchanged); biliary/fecal (minor, <5% total)
Ethinylestradiol and ethynodiol diacetate are extensively metabolized; urinary excretion accounts for ~40% of ethinylestradiol metabolites and ~50-60% of ethynodiol diacetate metabolites; fecal excretion accounts for ~30% of ethinylestradiol metabolites and ~35% of ethynodiol diacetate metabolites; biliary excretion contributes to enterohepatic circulation.
Ethinylestradiol: 97% bound to albumin; Norethindrone: 80% bound to albumin and SHBG
Ethinylestradiol: >97% bound, primarily to albumin, with ~2% bound to sex hormone-binding globulin (SHBG); ethynodiol diacetate (as norethindrone): ~95% bound, primarily to albumin and SHBG.
Ethinylestradiol: 2–4 L/kg; Norethindrone: 3–5 L/kg; large Vd indicates extensive tissue distribution
Ethinylestradiol: Vd ~2-4 L/kg; distributes extensively into body tissues; ethynodiol diacetate (as norethindrone): Vd ~4 L/kg; indicates wide distribution including reproductive tissues.
Oral: 40–60% (first-pass metabolism reduces systemic availability)
Oral: ethinylestradiol bioavailability ~40-60% due to first-pass metabolism; ethynodiol diacetate bioavailability ~60-80% after oral administration.
No dose adjustment required for chronic kidney disease. Contraindicated in acute renal failure or severe renal impairment (GFR <30 m L/min) due to potential fluid retention and electrolyte disturbances.
No dosage adjustment required for renal impairment. Use is not recommended in patients with severe renal impairment due to potential adverse effects.
Contraindicated in acute hepatic disease, hepatic adenomas, or impaired liver function (Child-Pugh class B or C). For mild hepatic impairment (Child-Pugh class A), use with caution; monitor liver function.
Contraindicated in patients with Child-Pugh C cirrhosis. For Child-Pugh A or B, use is generally not recommended; if used, monitor closely for adverse effects.
Not indicated for use in pediatric patients before menarche. Safety and efficacy in postmenarchal minors established; dose same as adults (one tablet daily for 21 days, then 7 days off).
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults: one tablet orally once daily for 28 days per cycle.
Not indicated for use in postmenopausal women. No specific dose adjustments for elderly due to lack of indication; consider increased risk of cardiovascular and thrombotic events in women over 35 who smoke.
Not indicated for use in postmenopausal women. No specific dose adjustment recommended for elderly, but consider increased risk of thromboembolic disorders.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day); women >35 years who smoke should not use this product.
Cigarette smoking increases risk of serious cardiovascular events (e.g., myocardial infarction, stroke, thromboembolism). Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Thrombotic disorders (thrombophlebitis, venous thromboembolism, arterial thromboembolism),Cardiovascular disease (e.g., myocardial infarction, stroke) especially in smokers >35,Liver disease (e.g., hepatic adenoma, hepatocellular carcinoma),Elevated blood pressure,Gallbladder disease,Carbohydrate/lipid metabolic effects,Ocular lesions (e.g., retinal thrombosis),Headache/migraine,Bleeding irregularities,Depression
Thromboembolic disorders (DVT, PE, stroke, MI),Hepatic neoplasia (benign/malignant liver tumors),Increased risk of gallbladder disease,Hypertension,Carbohydrate/lipid metabolic effects,Ocular disturbances (retinal thrombosis, optic neuritis),Depression,Fetal harm if used during pregnancy
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease,Known or suspected breast carcinoma,Endometrial or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Smoking and age >35 years
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease,Known or suspected breast cancer,Endometrial carcinoma or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component
No specific food restrictions; however, grapefruit juice may increase estrogen levels slightly (theoretical). Maintain consistent intake of folate-rich foods as oral contraceptives may lower folate levels. Avoid St. John's wort (herbal) as it reduces contraceptive efficacy.
No significant food interactions. Grapefruit juice may increase estrogen levels, but clinical significance is unclear. Maintain consistent intake of vitamin C-rich foods as they may increase estrogen absorption. Avoid St. John's wort, which reduces contraceptive efficacy.
Modicon 21 is a combination oral contraceptive. First trimester: Epidemiologic studies have not shown an increased risk of birth defects with inadvertent exposure. Second and third trimesters: Use is not indicated during pregnancy; fetal and neonatal risks include cardiovascular and genitourinary anomalies, though data are limited and confounded by maternal condition.
Contraindicated in pregnancy. First trimester: increased risk of neural tube defects, congenital heart defects, and limb reduction defects from progestins. Second and third trimesters: association with masculinization of female fetus, adrenal suppression, and possible long-term metabolic effects. Estrogen component may increase risk of VACTERL anomalies.
Combination hormonal contraceptives reduce milk production and may pass into breast milk. M/P ratio not established. Use in breastfeeding is generally not recommended until breastfeeding is well-established (typically after 6 weeks postpartum).
Contraindicated during breastfeeding. Estrogens reduce milk production and quality. M/P ratio not established; ethinyl estradiol and norgestrel are excreted in breast milk in small amounts, potentially causing adverse effects in the infant.
Not applicable as Modicon 21 is contraindicated during pregnancy. No dose adjustment is needed.
No adjustments; absolute contraindication in pregnancy. Drug should be discontinued immediately upon pregnancy diagnosis. No established safe dose in pregnancy.
MODICON 21 (norethindrone/ethinyl estradiol) is a monophasic oral contraceptive. Administer starting on day 1 of menstrual period (Sunday start or day 1 start). Breakthrough bleeding is common in first cycles; sustained bleeding warrants evaluation. Missed dose protocol: if one pill is missed, take it ASAP and continue schedule; if two or more missed, use backup contraception for 7 days. Advise against smoking due to increased thrombotic risk, especially in women over 35. Assess for contraindications: history of DVT/PE, migraine with aura, breast cancer, liver disease, uncontrolled hypertension, etc. Drug interactions: rifampin, anticonvulsants (phenytoin, carbamazepine), St. John's wort may reduce efficacy.
Demulen 1/50-28 is a monophasic combined oral contraceptive containing ethinyl estradiol 50 mcg and ethynodiol diacetate 1 mg. Due to the 50 mcg estrogen dose, it carries an increased risk of venous thromboembolism compared to lower-dose pills; avoid in patients with migraine with aura, hypertension >160/100 mm Hg, or age >35 who smoke. The 28-day pack includes 21 active pills and 7 placebo pills; breakthrough bleeding is more common with higher estrogen. Caution with hepatic enzyme inducers like rifampin or anticonvulsants may reduce efficacy.
Take one pill daily at the same time each day for 21 days, then 7 days off.,If you miss a pill, follow the missed dose instructions in the package insert.,Use backup contraception (e.g., condoms) if you miss two or more pills.,Do not smoke while taking this medication; smoking increases risk of blood clots.,Report any sudden severe headache, chest pain, leg swelling, or vision changes immediately.,You may experience irregular bleeding, nausea, or breast tenderness initially.,This medication does not protect against sexually transmitted infections.,Check with your doctor before starting any new medications, including herbal supplements.
Take one pill daily at the same time, preferably with food to reduce nausea.,The first 7 days of the first cycle require a backup contraceptive method if not starting on day 1 of menses.,Missed pill: if one active pill is missed, take it as soon as remembered and continue; if two or more active pills are missed, take the last missed pill, skip the others, use backup for 7 days, and consider emergency contraception.,Smoking increases risk of serious cardiovascular side effects; avoid smoking, especially if over 35.,Report symptoms of blood clots: sudden leg pain/swelling, chest pain, shortness of breath, or severe headache.,The 7 placebo pills are for withdrawal bleeding; start next pack on time regardless of bleeding.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MODICON 21 vs DEMULEN 1/50-28, answered by our medical review team.
MODICON 21 is a Combination Oral Contraceptive that works by Combination estrogen-progestin contraceptive; suppresses gonadotropins (FSH, LH) from pituitary via negative feedback, inhibiting ovulation; increases cervical mucus viscosity, impeding sperm penetration; induces endometrial thinning.. DEMULEN 1/50-28 is a Combination Oral Contraceptive that works by Combination oral contraceptive: Ethinyl estradiol and ethynodiol diacetate suppress gonadotropin secretion (LH, FSH) via negative feedback, inhibiting ovulation. Ethynodiol diacetate also increases cervical mucus viscosity and induces endometrial changes.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MODICON 21 and DEMULEN 1/50-28 depend on the specific clinical indication. These are both Combination Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MODICON 21 is: One tablet (norethindrone 0.5 mg and ethinyl estradiol 0.035 mg) orally once daily for 21 consecutive days, followed by 7 drug-free days.. The standard adult dose of DEMULEN 1/50-28 is: One tablet orally once daily for 28 consecutive days per cycle.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MODICON 21 and DEMULEN 1/50-28 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MODICON 21 is classified as Category C. Modicon 21 is a combination oral contraceptive. First trimester: Epidemiologic studies have not shown an increased risk of birth defects with inadvertent exposure. Second and third. DEMULEN 1/50-28 is classified as Category C. Contraindicated in pregnancy. First trimester: increased risk of neural tube defects, congenital heart defects, and limb reduction defects from progestins. Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.